Examining outlying subjects and outlying records in bioequivalence trials

Journal of Biopharmaceutical Statistics

Volumn 13, Issue 1, 2003, Pages 43-56

  Wang, Wenping ^a   Chow, Shein Chung ^b  

^a PHARSIGHT CORPORATION   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bioavailability; Bioequivalence; Likelihood; Mean shift model; Outlier

Indexed keywords

DRUG;

ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG FORMULATION; DRUG RESEARCH; PRIORITY JOURNAL; SAMPLING; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL;

BIOLOGICAL AVAILABILITY; BIOMETRY; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY;

EID: 0037284914     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-120017725     Document Type: Article

References (17)

1. Anderson, S., Hauck, W. W. (1990). Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 18(2):59-273.
2. Beckman, R. J., Cook, R. D. (1983). Outlier...s (with discussion). Technometrics 25:119-163.
3. Bolton, S. (1991). Outliers - Examples and Opinions. Presented at Bio-availability/Bio-equiva-lence: Pharmacokinetic and Statistical Considerations sponsored by Drug Information Association, August, 1991, Bethesda, Maryland.
4. Chow, S. C., Tse, S. K. (1990). Outlier detection in bioavailability/bioequivalence studies. Stat. Med. 9:549-558.
5. Cook, R. D. (1977). Detection of influential observations in linear regression. Technometrics 19:15-18.
6. Cook, R. D., Weisberg, S. (1980). Characterization of an empirical influence function for detecting influential cases in regression. Technometrics 22:495-508.
7. Cox, D. R., Hinkley, D. V. (1974). Theoretical statistics. Chapman & Hall.
8. FDA, (2000). Guideline for Industry: Bioavailability and Bioequivalence Study for Orally Administered Drug Products - General Considerations. Rockville, Maryland: Center for Drug Evaluation and Research, Food and Drug Administration.
9. Ferguson, T. S. (1961). On the rejection of outliers. Proceedings of the fourth Berkeley symposium on mathematical statistics and probability (Vol. 1). Berkeley and Los Angeles: University of California Press, pp. 253-287.
10. Ferguson, T. S. (1967). Mathematical statistics: a decision theoretic approach. New York: Academic Press.
11. Hawkins, D. M. (1980). Identifications of outliers. Chapman & Hall.
12. Liu, J. P., Weng, C. S. (1991). Detection of outlying data in bioavailability/bioequivalence studies. Stat. Med. 10:1375-1389.
13. Metzler, C. M., Huang, D. C. (1983). Statistical methods for bioavailability and bioequivalence. Clin. Res. Prac. Drug Regulat. Affairs 1:109-132.
14. O'Brien, P. C. (1984). Procedures for comparing samples with multiple endpoints. Biometrics 40:1079-1087.
15. Schuirman, D. J. (1987). A comparision of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 15:657-680.
16. Srikantan, K. S. (1961). Testing a single outlier in a regression model. Sankhȳ. Ser. A 23:251-260.
17. Westlake, W. J. (1976). Symmetrical confidence intervals for bioequivalence trials. Biometrics 32:741-744.